Abstract:Ferroptosis is a form of regulated necrosis associated with the iron-dependent accumulation of lipid hydroperoxides that may play a key role in the pathogenesis of degenerative diseases in which lipid peroxidation has been implicated. High-throughput screening efforts have identified ferrostatin-1 (Fer-1) and liproxstatin-1 (Lip-1) as potent inhibitors of ferroptosis - an activity that has been ascribed to their ability to slow the accumulation of lipid hydroperoxides. Herein we demonstrate that this activity likely derives from their reactivity as radical-trapping antioxidants (RTAs) rather than their potency as inhibitors of lipoxygenases. Although inhibited autoxidations of styrene revealed that Fer-1 and Lip-1 react roughly 10-fold more slowly with peroxyl radicals than reactions of α-tocopherol (α-TOH), they were significantly more reactive than α-TOH in phosphatidylcholine lipid bilayers - consistent with the greater potency of Fer-1 and Lip-1 relative to α-TOH as inhibitors of ferroptosis. None of Fer-1, Lip-1, and α-TOH inhibited human 15-lipoxygenase-1 (15-LOX-1) overexpressed in HEK-293 cells when assayed at concentrations where they inhibited ferroptosis. These results stand in stark contrast to those obtained with a known 15-LOX-1 inhibitor (PD146176), which was able to inhibit the enzyme at concentrations where it was effective in inhibiting ferroptosis. Given the likelihood that Fer-1 and Lip-1 subvert ferroptosis by inhibiting lipid peroxidation as RTAs, we evaluated the antiferroptotic potential of 1,8-tetrahydronaphthyridinols (hereafter THNs): rationally designed radical-trapping antioxidants of unparalleled reactivity. We show for the first time that the inherent reactivity of the THNs translates to cell culture, where lipophilic THNs were similarly effective to Fer-1 and Lip-1 at subverting ferroptosis induced by either pharmacological or genetic inhibition of the hydroperoxide-detoxifying enzyme Gpx4 in mouse fibroblasts, and glutamate-induced death of mouse hippocampal cells. These results demonstrate that potent RTAs subvert ferroptosis and suggest that lipid peroxidation (autoxidation) may play a central role in the process.

Inhibition of 7-dehydrocholesterol reductase prevents hepatic ferroptosis under an active state of sterol synthesis

7-Dehydrocholesterol Dictates Ferroptosis Sensitivity

7-Dehydrocholesterol is an endogenous suppressor of ferroptosis

The BRD7-P53-SLC25A28 axis regulates ferroptosis in hepatic stellate cells

Integrated hepatic ferroptosis gene signature dictates pathogenic features of ferroptosis

Research mechanisms of and pharmaceutical treatments for ferroptosis in liver diseases

Ferroptosis as an emerging therapeutic target in liver diseases

Characterization of Ferroptosis in Murine Models of Hemochromatosis.

AhR signaling modulates Ferroptosis by regulating SLC7A11 expression

Dimethyl Fumarate Protects Against Hepatic Ischemia-Reperfusion Injury by Alleviating Ferroptosis Via the NRF2/SLC7A11/HO-1 Axis

Research progress in ferroptosis regulation in the treatment of liver diseases

Luteolin attenuates CCl4-induced hepatic injury by inhibiting ferroptosis via SLC7A11

Cholesterol mediated ferroptosis suppression reveals essential roles of Coenzyme Q and squalene

Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications

Exploring the Updated Roles of Ferroptosis in Liver Diseases: Mechanisms, Regulators, and Therapeutic Implications

Targeting ferroptosis with natural products in liver injury: new insights from molecular mechanisms to targeted therapies

Dynamic regulation of ferroptosis by lipid metabolism.

Understanding the unique mechanism of ferroptosis: a promising therapeutic target

Nrf2-Mediated Ferroptosis Inhibition Exerts a Protective Effect on Acute-on-Chronic Liver Failure

On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death

The prospects of ferroptosis in the pathogenesis of liver disease